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1. Introduction 
Ovarian cancer represents the leading cause of death from gynaecological cancers especially 
because it relapses in most of the cases. 
Central nervous system and especially the encephalon are very often involved in 
metastatic process arising from malignancies coming from many different sites in the 
whole body. 
The incidence of brain involvement in metastatic tumours was estimated to be around 25%, 
that represents a very large proportion and moreover, around 20% of the lesions found 
within the central nervous system are diagnosed as secondary locations of a wide spread 
cancer. 
The most common tumours that present brain involvement are lung, breast cancers and 
melanomas, while the gynaecological malignancies contribute around 2% of all the brain 
metastases, except the trophoblastic diseases that involve the central nervous system in 
around 30% of the cases. 
Anyway, although it was believed that central nervous system involvement from epithelial 
ovarian cancer was very uncommon, it is increasing of incidence. 
Moreover, the comprehension of how to diagnose and treat these metastases is very 
important because they are usually characterized, more than the most common liver or 
lung metastases, by symptomatology that can severely affect the quality of life of these 
patients. 
This new finding points out whether or not is appropriate to ask for a brain image 
technique in the follow up of ovarian cancer patients, and which therapy should these 
women receive. 
Today, there are new possible therapeutic approaches including stereotactic radiosurgery, 
the administration of new effective and with less side effect chemotherapy agents, moreover 
the improvement in the neurosurgery techniques makes craniotomy from brain metastases a 
less riskful procedure with better outcomes.  
Aim of his chapter is to analyse the clinicopathological features of these patients, the 
diagnosis and the different therapeutic approaches based on our experience and on all the 
series published in literature in the last 15 years. 
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2. Incidence 
Central nervous system involvement from ovarian cancer is an uncommon event, but many 
studies published in literature agree that it is increasing in incidence. (Cormio, 2011a; 
Cormio 2011b; Pectasides, 2006) 
The analysis of two reports present in literature about the biological behaviour of ovarian 
cancer in autopsied patients reveals that 1 out of 158 women with this tumour actually 
present a brain involvement. (Bergman, 1966; Julian, 1974) 
In literature, the reported incidence ranges from 0.29 to 4.5%. (Larson, 1986; Stein, 1986; 
Leroux, 1991; Rodriguez, 1992; Geisler J.P. & Geisler H.E., 1995; Kaminsky-Forrett, 2000) In 
our recent series of 20 patients the incidence estimated was 5%. (Cormio, 2011a)  
This increased incidence can be the result of three different aspects. First of all the advances in 
the production and management of the new chemotherapy agents have guaranteed in the last 
years a prolongment of life of these patients; this increased time allows the tumour to implant 
and grow in distant sites. Secondly, the improvement of brain image techniques allowed 
detecting very small lesions. Finally, the use of chemotherapy agents that seem to pass poorly 
the blood brain barrier results in the growth of cancer cells within the nervous tissue.  
3. Ways of spread to the central nervous system 
Ovarian cancer usually spreads locally into the peritoneal cavity, while the lymphatic and 
haematogenous route are possible but rare. Distant metastases are found in about 30% of 
patients and the most common localizations are liver, lungs and pleura. (Cormio, 2003a) 
The dissemination of the ovarian cancer into the brain seems to occur in three possible way: 
via the haematogenous spread, by direct invasion of the nervous tissue after bony 
involvement, or in case of leptomeningeal carcinomatosis, through retrograde lymphatic 
spread (Pectasides, 2006)  
The mechanism of meningeal dissemination is still not known, but hypothetically it should 
be caused by a direct invasions of the liquor through the choroid plexus, by a rupture of the 
brain lesions into the ventricles or subarachnoid space, or by infiltration either of the small 
veins in the arachnoid membrane, either of the lymphatic vessels. (Cormio, 2007). 
4. Clinicopathological characteristics of the primary tumour 
Different series published in literature in the last 15 years, agree that most commonly these 
metastases arise in patients with an advanced stage (FIGO stage III or IV), serous hystotype 
and poorly differentiated (G3) primary ovarian cancer (see Table 1). (Anupol, 2002; Brown 
III, 2005; Chen, 2009; Cohen, 2004; Cormio, 1995, 2003b, Cormio, 2011a; D'Andrea, 2005; 
Kastritis, 2006; Kim, 2007; Kumar, 2003; Lee, 2008; Sanderson, 2002; Sehouli, 2010; Tay & 
Rajesh, 2005). However Kolomainen et al. demonstrated in their series that a brain 
involvement could be seen quite frequently (one third of their patients) also in patients with 
FIGO stage I. (Kolomainen, 2002) 
The median age at presentation of the ovarian cancer in patients who present brain 
involvement in the same series is 55,1 years, ranging from 46,7 to 60,3 years. 
In most of these studies, patients were treated with the standard procedure consisting in 
primary optimal debulking surgery followed by platin-based chemotherapy; in particular 
patients of our recent study received six courses of taxol and carboplatin (Cormio, 2011a) 
www.intechopen.com
 
Central Nervous System Involvement from Epithelial Ovarian Cancer 
 
89 
Clinical 
series (year) 
No of 
patients 
Incidence 
Median 
age at 
ovarian 
cancer 
diagnosis 
(year) 
Advanced 
stage 
disease 
(III-IV) 
Poorly 
differentiated, 
G3 cancer 
Serous 
hystotype 
Cormio 
(1995) 
23 - 59 20 (87%) 17 (74%) 14 (61%) 
Anupol 
(2002) 
15 1,4% 58 15 (100%) 12 (80%) 14 (93,3%) 
Pothuri 
(2002) 
14 - 59,3 13 (92,8%) 10 (71,4%) 9 (64,3%) 
Sanderson 
(2002) 
13 1,1% 55 13 (100%) - 3 (23%) 
Cormio 
(2003) 
20 - 54 20 (92%) 12 (55%) 15 (68%) 
Kumar 
(2003) 
18 2,7% 54 16 (88,9%) 11 (55,5%) 13 (72,2%) 
Cohen 
(2004) ¹ 
72 0,9% 50,4 52 (81%) 52 (83%) 14 (24%) 
D'Andrea 
(2005) 
11 - 60,3 0 - 11 (100%) 
Tay & 
Rajesh 
(2005) 
4 0,66% 52,5 3 (75%) - 2 (50%) 
Brown III  
(2005) 
3 - 46,7 3 (100%) - 2 (66,7) 
Kastritis  
(2006) ² 
8 3%² 59 8 (100%) 6 (75%) 6 (75%) 
Kim (2007) 13 2,7% 52 12 (92,3%) 7 (53,8%) 9 (69,2%) 
Lee (2008) 15 1% 55 14 (93,3%) - 8 (53,3%) 
Sehouli  
(2010) 
74 1,7% 53,9 62 (83,8%) 43 (58,1%) 53 (71,6%) 
Chen (2011) 10 1,9% 56,6 9 (90%) 6 (60%) 7 (70%) 
Cormio  
(2011a) 
20 5% 55.5 19 (95%) 15 (75%) 14  (70%) 
 
- data not available 
¹ this study analyses all the ovarian cancer patients and not just the epithelial ones. Anyway most of 
patients with CNS metastases, when data were available, had a epithelial hystotype (about 93%) 
² this study analyses only patients presented with brain involvement as isolated site of relapse, for this 
reason we decided not to include the incidence here calculated in the final results 
 
Table 1. Clinicopathological characteristics of the primary ovarian cancer. 
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5. Clinicopathological characteristics of brain metastases 
5.1 Pathology 
Metastatic tumour to the brain can involve the Dura Mater and the cranial bones arising 
especially from breast or prostatic cancer, the leptomeninges leading to a meningeal 
carcinomatosis, the encephalon or the spinal cord. Metastases in the encephalon usually 
involve the cerebral and cerebellar hemispheres, less frequently the brainstem and the basal 
ganglia. Brain metastases usually arise in the zone within the cortex and the white substance 
that is very vascularized, only rarely they arise deeply.  
Macroscopically brain metastases usually appear as grey-red nodular lesions, with or 
without necrotic or haemorrhagic areas. (Maiuri, 1992) 
Central nervous system metastases from epithelial ovarian cancer are usually multiple and 
localized into the brain hemispheres, followed by the cerebellum; rarely they involve the 
spinal cord or a leptomeningeal dissemination is discovered. The median interval from the 
time of primary cancer diagnosis to the brain involvement findings is 32 months in 
published studies, but in some patients the brain metastases can be found as the first 
manifestation of the tumour, and only a deep investigation can reveal the ovarian origin. 
The majority of these women usually present extracranial localizations of the disease, within 
or not the peritoneal cavity. (See Table 2, Figures 1, 2, 3, 4) 
 
 
Fig. 1. Cerebral metastases from epithelial ovarian cancer. 
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Clinical series 
(year) 
Mean 
interval to 
CNS 
metastases
(months) 
Patients 
with 
extracranial 
disease (%) 
Number of 
CNS lesions 
Localization 
Single MultipleCerebralCerebellar
Miscellaneous, 
meningeal 
Cormio 
(1995) 
35 
14  
(61%) 
9  
(41%) 
13 
 (59%) 
18 
(78,3%) 
4  
(17,4%) 
1  
(4,3%) 
Anupol 
(2002) 
15 
7  
(%) 
8 
(53,3%) 
7  
(46,7%) 
- - - 
Pothuri 
(2002) 
42 
8  
(57%) 
12 
(85,7%) 
2  
(14,3%) 
12 
(85,7%) 
2  
(14,3%) 
0 
Sanderson  
(2002) 
36 
8  
(61,5%) 
8 
(61,5%) 
5  
(38,5%) 
9 
(69,2%) 
2  
(11,4%) 
2  
(11,4%) 
Cormio 
(2003) 
29 
13  
(59%) 
- - 
18  
(82%) 
4  
(18%) 
0 
Kumar 
(2003) 
29 
13  
(72,2%) 
5 
(27,8%) 
13 
(72,2%) 
13 
(72,2%) 
2  
(11,1%) 
3  
(16,7%) 
Cohen 
(2004) ¹ 
22 
41  
(57%) 
25 
(35%) 
47  
(65%) 
19  
(27%) 
6  
(8%) 
47, 3  
(65%) 
D'Andrea  
(2005) 
21 0 
11 
(100%) 
0 
9 
(81,8%) 
2  
(18,2%) 
0 
Tay & Rajesh 
(2005) 
16,5 
4  
(100%) 
0 
4  
(100%) 
1 
(25%) 
0 
3, 1  
(75%) 
Brown III  
(2005) 
19 0 
1 
(33,3%) 
2  
(66,7%) 
0 
1  
(33,3%) 
2  
(66,7%) 
Kastritis 
(2006) ² 
17,2 0 
4  
(50%) 
4  
(50%) 
- - - 
Kim 
(2007) 
28 
7  
(53,8%) 
2 
(15,4%) 
11 
(84,6%) 
6 
(46,2%) 
1  
(7,7%) 
6  
(46,1%) 
Lee 
(2008) 
28 ³ 
5  
(33,3%) 
5 
(33,3%) 
10  
(66,7%) 
- - - 
Sehouli 
(2010) 
28,8 
35 
(47,3%) 
26 
(21,4%) 
48 
(64,8%) 
- - - 
Chen 
(2011) 
24,3 
7  
(70%) 
1  
(10%) 
9  
(90%) 
   
Cormio 
(2011a) 
32,7 
11  
(55%) 
11 
(55%) 
9  
(45%) 
9  
(45%) 
5  
(25%) 
6  
(30%) 
 
- data not available 
¹ this study analyses all the ovarian cancer patients and not just the epithelial ones. Anyway most of 
patients with CNS metastases, when data were available, had a epithelial hystotype (about 93%) 
² this study analyses only patients presented with brain involvement as isolated site of relapse, for this 
reason we decided not to include the incidence here calculated in the final results 
³ in this value are excluded two patients whose brain involvement was discovered at the same time of 
the ovarian cancer findings 
 
Table 2. Clinicopathological characteristic of the brain metastases. 
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Fig. 2. Cerebellar metastases from epithelial ovarian cancer. 
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Fig. 3. Single brain metastases from epithelial ovarian cancer. 
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Fig. 4. Multiple brain metastases from epithelial ovarian cancer. 
5.2 Clinical manifestations 
The symptoms at the diagnosis of these metastases, like all central nervous system tumours, 
can be mild usually with an unspecific symptomatology or severe with, for example 
epilepsy or focal neurological deficit. 
In some cases the metastases can be diagnosed after a stroke, caused by an embolism of 
cancer cells; in these cases usually the patients at first complain of some sort of neurological 
deficit that can resolve in few days, but some weeks after the clinical manifestations get 
quickly worse for the implant and growth of the cancer. (Maiuri, 1992) 
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Patients with central nervous system dissemination from ovarian cancer most commonly 
complain of headache, which is probably a consequence of the increased intracranial 
pressure caused by the oedema or the hydrocephalus, more then a consequence of the mass 
of the lesion itself.  
Other symptoms that are often described are vomiting, confusions, visual disturbances, 
paresis, and weakness, loss of consciousness, seizures, and dizziness. (Cohen, 2004; Cormio, 
2003; Cormio, 2011a; D'Andrea, 2005; Lee, 2008; Pectasides, 2006; Tay &Rajesh, 2005) 
The leptomeningeal involvement usually causes an arise of the intracranial pressure 
associated with hydrocephalus; these patients more frequently than the others complain also 
for bowel of bladder dysfunctions, while the involvement of cranial nerves can also be 
possible. (Pectasides, 2006; Vitaliani R, 2009) 
In our recent series of 20 patients, all patients were symptomatic at the moment of the 
diagnosis; most of them complain of headache, vomiting and dizziness with or without 
balance disturbances, less frequent symptoms were diplopia, convulsions, amnesia, 
confusion and pain. One patient had a left hemiparesis caused by a metastases localized in 
the right parietal lobe. (Cormio, 2011a) 
6. Diagnosis 
The diagnosis is usually suspected when a patient with ovarian cancer complains about any 
neurological symptoms, although asymptomatic cases are not infrequent. The symptoms 
themselves can already also suggest the localization of the lesions in some cases.  
6.1 Imaging features  
It is necessary, in our opinion, to perform either a computed tomography (CT) scan or a 
magnetic resonance imaging (MRI) in any patient with a history of ovarian cancer, who has 
any neurological defect. 
Usually the first diagnosis is done both by the clinical examination that reveals neurological 
signs and by pre and post contrast CT scan, less commonly clinicians ask for an MRI. 
The two image techniques are both effective, even if MRI seems to be the modality of choice 
because it has an higher resolution than CT scan, it is able to detect lesions as small as 1,9 
mm; moreover MRI seems to be more effective especially for the image study of the lesions 
localized in the posterior fossa. (Pectasides, 2006).  
In a CT scan, metastatic lesions appear as ring areas, singular or multiple, slightly hyper 
dense, homogeneous or not and commonly surrounded by oedema. Sometimes the 
metastases can have a hypo dense core for the presence of central necrosis or of a central 
abscess, which can sometimes simulate the diagnosis of an inflammatory abscess. 
The administration of an intravenous contrast medium has been shown to enhance the 
sensitivity of the technique, moreover Davis et al also demonstrated that a delaying imaging 
after the administration and an increased volume of contrast also can increase the detection 
rate. (Davis, 1991) 
In MRI the brain metastases appear as hypo intense nodular areas, the administration of the 
contrast medium (gadolinium) enhances the intensity in the image.  
The most important differential diagnosis should be done with primary brain tumours, 
vascular conditions like strokes or haemorrhages and intracranial abscess.  
www.intechopen.com
 
Ovarian Cancer – Clinical and Therapeutic Perspectives 
 
96
Metastatic lesions, usually, can be differentiated from primary central nervous system 
tumours, because more frequently they are multiple and surrounded by larger areas of 
oedema (larger than primary tumours of the same size). Finally, the metastatic lesions  
Further studies should investigate the benefits of using new image techniques as positron 
emission tomography or magnetic resonance spectroscopy for the diagnosis of central 
nervous system involvement from epithelial ovarian cancer. 
6.2 Leptomenigeal carcinomatosis  
The meningeal carcinomatosis from epithelial ovarian cancer is often difficult to diagnose, in 
fact CT scans even with contrast medium injection can be negative.  
CT images usually show the presence of solid areas in the parenchyma and hydrocephalus 
(Chung, 2001), but not directly the presence of leptomeningeal metastases. For this reason 
the presence of meningeal involvement should be suspected in patient with ovarian cancer 
and hydrocephalus, and further investigations should be performed.  
The image of choice in these patients is the contrast enhanced MRI, while the non-contrast 
one has been showed to be as ineffective as CT scan. (Collie, 1999)  
In patients with meningeal carcinomatosis the diagnosis can be done also by the cytological 
analysis of the cerebrospinal fluid that reveal the presence of ovarian cancer malignant cells. 
(Pectasides, 2006) 
6.3 The role of Ca125  
The serum marker Ca125 is the strongest tumour marker for the presence of ovarian cancer. 
An increased value of Ca125 can be or not observed in patients with brain involvement from 
ovarian cancer.  
In our experience we noticed that usually it arises in patients with brain involvement, who 
were already found to have high concentration of the tumour marker at the first diagnosis of 
the ovarian cancer, even if sometimes it arises also in patients without an history of 
increased Ca125, or it does not arise in patients for whom this lab value was used as a strong 
and efficient marker of the presence of the cancer during the previous therapies.  
In any case, as for the primary ovarian cancer in patients with positive Ca125, this marker can 
be used during and after the therapy of the brain metastases in order to assess the response of 
the cancer to the treatment and the presence or absence of the disease during the follow up. 
7. Therapy 
7.1 Treatments options and clinical decisions  
When it comes to decide about the different types of treatments, the first things to think 
about is the quality of life of these patients, in fact in very few cases limited to those patients 
with a good performance status, single metastases and without any sign of extracranial 
disease the intent of the therapy can be curative.  
As already showed, a large proportion of these patients present with extracranial disease 
and multiple metastases, in these women it is very unlikely that any treatment of central 
nervous system metastases chosen can be curative, so the primary roles of the therapy must 
be the improvement of symptoms, the avoidance of life threatening conditions and the 
increase of life expectance.  
Moreover, other important things to consider are the patients performance status, age, 
status of the disease, previous treatments and their results. All these aspects added to the 
www.intechopen.com
 
Central Nervous System Involvement from Epithelial Ovarian Cancer 
 
97 
clinicopathological characteristics of the metastatic brain lesions should be strictly studied to 
assess the risk-benefit of each treatment modality. 
Treatment options are: in emergency the therapy of the life threatening complications like 
increased intracranial pressure, obstructing hydrocephalus and severe epilepsy, no 
treatment in patients not eligible of any therapy, corticosteroids, radiotherapy administrated 
as whole brain radiotherapy or stereotactic radiosurgery, surgery and chemotherapy.  
Due to the rarity of these metastases, this condition has not already had any guidelines that 
can be followed in the choice of treatment, for this reason is very important that the expert 
gynaecologist oncologist cooperate with the neuroradiologist and the neurosurgeon in order 
to decide what is best management for each patients with brain involvement from epithelial 
ovarian cancer.  
7.2 Corticosteroids, mannitol and antiepileptic agents 
The intracranial oedema is very common in women with brain metastases from epithelial 
ovarian cancer; it results from the damage of the blood brain barrier caused by the tumour 
itself that leads to an increase of the barrier permeability, with a passage of sodium and 
water molecules into the brain tissues.  
For this reason almost all patients with this condition is eligible of receiving corticosteroids 
therapy just after the first diagnosis of brain involvement. In fact, corticosteroids are very 
effective drugs especially in reducing the surrounded oedema of these metastatic lesions, 
resulting in a decrease of intracranial pressure.  
The mechanism of action of corticosteroids is to decrease the oedema by decreasing the 
permeability of the blood brain barrier and the passage of water and ions into the cerebral 
parenchyma. This drugs in long term administrations can lead to severe side effects like 
diabetes and hyperglycaemia, osteoporosis, hypertension, thyroid deficiency, 
hypogonadism and male impotence, cataract and several others.  
The preferred molecule is the dexamethasone because of its lower mineralocorticoids effects 
that results in fewer side effects. The starting dose is usually 4 mg administered 
intravenously or orally 4 times daily, after the stabilization of the clinical manifestations the 
dose should be gradually decreased in a long period of few weeks, to reduce the side effects 
of a long corticosteroid treatment on the entire metabolism of the patients.  
Corticosteroids administered in patients with metastatic brain involvement from epithelial 
ovarian cancer, results in few hours (usually 6- 24 hours) in the improvement of the 
headache and the generalized neurological symptoms, while the focal neurological deficits 
are less effectively improved.  
The maximum result is seen usually after few days of corticosteroids treatment, but in a 
large number of patients their action lasts after some days from the end of the 
administration.   
Mannitol is an osmotic diuretic that administered intravenously is effective in reducing 
intracranial pressure in acute cases, but with repeated administration can give a rebound 
effect and worsen the oedema, for this reason is used only for acutely decompensating 
patients in association to corticosteroids. 
Some patients with brain involvement from ovarian cancer can develop convulsions and 
epilepsy. The prophylactic use of anticonvulsant agents is not indicated, but in patients who 
present epilepsy these should be administered; the most common drugs used in the clinical 
practice are the valproate, phenobarbital, phenytoin and carbamazepine. Phenytoin is our 
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anticonvulsant of choice because it is usually effective, well tolerated and it can be 
administered both parenterally and orally.  
Corticosteroids and mannitol with or without valproate or other antiepileptic drugs are 
usually administered in patients with multiple metastases and bad clinical conditions. 
Several studies present in literature demonstrated that the median survival after brain 
metastases involvement diagnosis in patients treated with corticosteroids alone is about 2 
months, and that this value is similar to the median survival obtained in patients treated 
with palliative therapy with any kind of central nervous system metastatic disease. (Cohen, 
2004; Kaminsky-Forrett, 2000; Pectasides, 2005; Pectasides, 2006; Markesbery, 1978; 
Ruderman, 1965) 
7.3 Radiotherapy  
The irradiation of the entire brain (whole brain radiotherapy) has been considered for years 
alone or after surgery, or with chemotherapy the modality of choice in the treatment of 
metastatic malignancies to the brain with or without extracranial disease. The standard dose 
for patients who are not eligible of surgery is 30 Gy administered in 10 fractions over a 
period of 2 weeks. Higher daily doses can be administered to reduce the duration of the 
treatment, but they cause more commonly a late onset encephalopathy, a severe condition 
that should be avoided especially in patients with a higher life expectancy. (Dropcho, 1991; 
Rottenberg, 1977).  
This therapeutic approach can actually increase survival and relieve symptoms by reducing 
the oedema. It is effective in most patients on the headache, convulsions, cognitive and other 
neurological deficiency, moreover it also let to decrease the corticosteroids doses. Series of 
patients present in literature who received a uni modal treatment consisting only in whole 
brain radiotherapy revealed that it leads to a median survival of about 5 months, ranging 
from 1,5 to 27 months. (Cohen, 2004; Kaminsky-Forrett, 2000; Kumar, 2003; Pectasides, 2006; 
Sood, 1996) 
7.4 Stereotactic radiosurgery  
Stereotactic radiosurgery represents an important alternative to the surgical approach. It is a 
special form of radiotherapy where high doses of radiatons are delivered to the metastases 
using a linear accelerator or, in gamma knife radiosurgery, using a gamma knife without 
any surgical incision. (Edwend, 2001; Lassman, 2003; Monaco, 2008; Yo Kyung Lee, 2008) 
The administered dose is inversally proportioned to the diameter of the lesion; usually for 
lesions smaller than 3 cm the dose is 18-20 Gy. These metastases are usually small, circular 
and with radiological margins well defined. More than primary brain tumours, metastatic 
brain tumours are suitable of being treated with stereotactic radiosurgery. (Soffietti, 2002) 
Stereotactic surgery has been proven in several reports to be a good therapeutic approach 
for patients with brain metastases, because these cause rapid reduction of the 
symptomatology and of the dimensions of the lesions, with lower invasiveness. 
This radiotherapy technique has a lower morbidity than surgical approach and so can be 
admistered also in local anesthesia in patients with systemic clinical conditions that are not 
suitable for general anesthesia; moreover it has also economic advantages because it does 
not required hospitalization. 
When comparing radiosurgery with whole brain radiotherapy, it is proven that the first one 
has less long term side effects, such as cognitve problems. 
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Patients who are eligible for it are especially those with small metastases, deep seated and so 
surgically inaccesible lesions. (Monaco, 2008; Combs, 2004) 
Anyway, there are some controversial in literature about the role of stereotactic 
radiosurgery, for example studies showing that these techniques does not have any impact 
on survival (Andrews, 2004) or that it improves outcomes only in patients with single 
metastases and not with multiple ones. (Pectasides, 2006) 
In conclusion, for these reasons stereotactic radiosurgery is now preferred for those patients 
who are not eligible for surgery, with single lesions or with deep seated surgically 
inaccesible metastases. 
7.5 Surgery  
Surgical management can be used with different aims. First of all it can be used in case the 
diagnosis is not clear, in fact the histological examination done after surgery can clarify the 
diagnosis especially in those cases where the brain involvement is the first sign of the 
ovarian cancer and there is no clear evidence of the presence of the primary disease. 
Secondly, surgical approach can be also used to reduce the symptoms by removing the 
lesions and so the pressure that the mass causes on the brain parenchyma. Finally, surgery 
can be used with curative aims or in every case it is necessary to control the local 
intracranial disease to improve the clinical conditions and let clinicians administer other 
treatments for the systemic disease. 
Many studies demonstrated that the surgical approach represents the best treatment 
modality for patients with brain involvement from epithelial cancer that are eligible for it. 
(Cormio, 2003; Cormio, 2011a; Cormio, 2011b; Pothuri, 2002) 
For patients who are not good candidates, with extracranial sign of disease or multiple 
metastases, craniotomy can control symptomatology, avoid life-threatening complications; 
improve quality of life and also overall survival. (Buckner, 1992; Pectasides, 2006) 
In a series of 56 patients, treated in our centre, with a diagnosis of central nervous system 
metastases from ovarian carcinoma, 22 underwent surgical resection of solitary brain 
metastases and survived 16 months, while the other 34 women, who were not eligible for 
surgery, survived only 4 months. (Cormio, 2003) 
In conclusion the surgical approach should be chosen always if there are the following 
conditions:  
 the cerebral metastases are single and superficial 
 There are no radiological signs of the presence of the disease at other sites, or the 
activity of the primary tumour is well control 
 The clinical conditions of the patients are good 
7.6 Chemotherapy 
The role of chemotherapy in the treatment of brain metastases from ovarian cancer is still 
on debate. As already précised above, the increasing rate of these metastases observed in 
the last few years has been attributed to chemotherapy drugs. (Lassman, 2003; Lesser, 
1996). 
This therapeutic approach has some advantages, such as the simple way of administration 
that in most cases can be done on outpatient basis or with few days hospitalization, its 
action on cancer cells that can be eventually presents in the whole body and the fact that it 
does not damage the brain tissues causing dementia or brain atrophy (Pectasides, 2006) 
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On the other side, the poor clinical conditions of some patients, the aggressivity of these 
treatments and the fact that many chemotherapy agents seem not to pass the blood brain 
barrier can contraindicate this procedure. 
Many authors demonstrated that chemotherapy actually results in a remission of the disease 
and in an increased survival (Cooper, 1994; Cormio, 1995, Rodriguez, 1992; Watanabe, 2005) 
An analysis conducted on 15 studies by Mc Meekin et al showed that chemotherapy has an 
important role because is the only therapeutic approach that, as the surgical treatment, 
really improves survival. (Mc Meekin, 2001). 
The best choice for their ability to pass the blood brain barrier seem to be cisplatin and other 
platin-based drugs, etoposide, gemcitabine, docetaxel (Cormio, 1995; Melichar, 2004; 
Rodriguez, 1992; Vlasved, 1990; Salvati, 1994; Watanabe, 2005) 
7.7 Multimodal approaches 
In our experience but also in several series reported in literature the best approach for 
patients with brain involvement from epithelial cancer seems to be the multimodal 
approach; in our recent study, we demonstrated that craniotomy followed by 
radiotherapy and/or chemotherapy results in median survival of about 18 months. 
(Cormio, 2011a). 
The best multimodal approach is supposed to have a double effect, on one side a local 
therapy such as craniotomy or stereotactic radiosurgery or whole brain radiotherapy is 
administered to remove and control the local spread of the cancer within the brain, on the 
other side the systemic treatment is able to control the wide spread of the disease. 
In conclusion, the best combinations of therapies, from our experience, are surgery plus 
radiotherapy and eventually chemotherapy that in our opinion is the best choice for patients 
with extracranial disease, stereotactic radiotherapy plus whole brain radiotherapy and 
eventually chemotherapy. 
7.8 Therapy of neoplastic meningitis  
The neoplastic meningitis has been reported in very few studies, for this reason the 
therapeutic approach that should be chosen for this patients is currently not defined. 
The therapy of neoplastic neoplastic meningitis usually consists in radiotherapy and 
intracerebrospinal fluid chemotherapy like intrathecal methotrexate (Chamberlain, 2005; 
Cormio, 2007). 
Most patients who present leptomenigeal dissemination of ovarian cancer have also a wide 
spread dissemination of the disease, with poor clinical conditions and aggressive treatments 
that are usually indicated in these conditions can give more damages than benefits; for this 
reason plus the fact that the choice of any clinical approach must take into account first of all 
the improvement of the quality of life of these patients, the treatment choice is usually very 
difficult and must be decided for each patients. 
8. Survival and prognostic factors 
Although many efforts and improvements in diagnosis and treatment of central nervous 
system metastases from epithelial ovarian cancer have been already reached, the prognosis 
of this condition is still poor. In the studies present in literature the overall survivals 
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calculated from the time of the diagnosis of the brain involvement range from 4 to 10 
months. (Table 3, Figure 5) 
 
Clinical series (year) Survival (months) ¹ 
Cormio (1995) 5 
Anupol (2002) 6 
Pothuri (2002) 18 
Sanderson (2002) 4 
Cormio (2003) ² 16 
Kumar (2003) 4 
Cohen (2004) 6,27 
D'Andrea (2005) ³ 28 
Tay & Rajesh (2005) 19,5 
Brown III (2005) - 
Kastritis (2006) - 
Kim (2007) 7 
Lee (2008) 14 
Sehouli (2010) 6,2 
Chen (2011) 3 
Cormio (2011a) 17,6 
 
 
- data not available 
¹ the survival was calculated from the time of diagnosis of CNS metastases 
² this study analyses only patients with solitary brain metastases who underwent surgical resection 
³ this study analyses only patients treated with surgical en bloc removal and postoperative radio-
chemotherapy 
Table 3. Survival in the series present in literature. 
www.intechopen.com
 
Ovarian Cancer – Clinical and Therapeutic Perspectives 
 
102 
 
Fig. 5. Survival in the series present in literature. 
Different studies present in literature demonstrated that the prognostic factors that 
significantly affect survival of patients with brain involvement from ovarian cancer are the 
presence of extracranial disease, the number of brain metastases and the treatment 
approaches (multi-modal therapy prolong survival in most of the studies. The prognostic 
factors of each study analysed are shown in Table 4. 
9. Changes from the past and future prospective 
In a recent study (Cormio, 2011b), we compared the a series of patients from 1995 and a 
series of patients from 2010 all with diagnosis of epithelial ovarian cancer and brain 
metastases in order to assess the difference in management and outcomes of this condition. 
We demonstrated that, even if the clinicopathological features both of the primary tumour 
and the metastases were similar in the two groups, the survival triplicate in the last 15 years 
going from 5 months to 18 months. This difference can be attributed to the change in the 
therapeutic approach. In fact, while in 1995 the therapy was given more with palliative 
intent, nowadays clinicians are more likely to administer more aggressive and multimodal 
treatments, with the intent of both improving the quality of life and the overall survival. 
(Anupol, 2002; Brown III, 2005; Chen, 2009; Cohen, 2004; Cormio, 1995; Cormio, 2003b; 
Cormio, 2011a; D'Andrea, 2005; Kastritis, 2006; Kim, 2007; Lee, 2008;  Sanderson, 2002; 
Sehouli, 2010; Tay & Rajesh, 2005) 
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Study Prognostic factors  
Cormio (1995) 
- number of lesions 
- extracranial disease 
- treatment (P vs RT vs O RT) 
Anupol (2002) 
- extracranial disease 
- treatment (survival with RT+O+CT > RT+O 
>RT+CT>RT) 
Cormio (2003) 
- extracranial disease 
- interval between ovarian cancer diagnosis and brain 
involvement findings 
- treatment ( survival with O > no O) 
Kumar (2003)  
- serous hystotype  
- grade (survival in I-II > III- IV) 
- optimal primary surgery  
- extracranial disease 
Cohen (2004) 
Univariate analysis 
- extracranial disease 
- treatment (RT+O > RT or O alone> P)  
Multivariate analysis  
- treatment (RT+O > RT or O alone> P)  
Kim (2007) 
Univariate analysis 
- Karnofsky performance status > 70 better prognosis 
- primary lesion (controlled vs not controlled) 
- number of CNS metastases (single > multiple) 
- RPA prognostic classification (I >II>III) 
- extracranial disease 
- treatment (GKRS vs without GKRS)  
Multivariate analysis 
- RPA prognostic classification (I >II>III) 
- treatment (GKRS vs without GKRS)  
Lee (2008) - treatment (GKRS > WBRT) 
Sehouli (2010)  
- number of CNS metastases (single > multiple) 
- Karnofsky performance status > 60 better prognosis 
- platinum sensitive diseases have better survival 
- grading  
- FIGO stage 
NB: no multimodal therapy and extracranial 
metastases  
Cormio (2011a) 
- FIGO stage 
- extracranial disease 
- treatment (O >no O; multimodal>unimodal 
treatment) 
- response after brain metastases therapy (complete > 
incomplete or absent)  
 
Table 4. Prognostic factors in the studies present in literature. 
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Future efforts can be put on one side, on the improvement of early diagnosis by the 
investigation of the role of new imaging techniques such as positron emission tomography 
and magnetic resonance spectroscopy in the detection of brain metastases, and on the other 
side on the improvement of treatment modality with higher efficacy and lower morbidity 
like the new radio surgical techniques. Although many authors agree that a multimodal 
approach results in better prognosis, further studies should be done to fix some guidelines 
for the treatment of these patients.  
Finally, further studies are also needed to investigate the role of chemotherapy especially in 
patients with both brain metastases and extracranial metastases from ovarian cancer, in 
order to find a therapy that can control both the local and systematic manifestations of these 
cancer. 
10. Conclusions 
In conclusion, even if brain metastases from ovarian cancer have always been considered an 
uncommon event, they are increasing of incidence. All patients with ovarian cancer who 
present neurological symptoms must undergo a CT or MRI scan of the brain.  
The treatment choice must take into account the clinicopathological characteristics of the 
metastases and of primary cancer, the presence of extracranial disease and obviously the 
performance status of the patients. Moreover the therapy should be aim both to have a 
remission of the disease and to improve the quality of life.  
Patients with poor performance status and/or multiple and not isolated metastases usually 
undergo palliative therapy consisting in mannitol, corticosteroids and anticonvulsant. In 
patients who are eligible for therapy the possibilities include: craniotomy, stereotactic 
radiosurgery (including the new gamma knife one), whole brain radiotherapy and 
chemotherapy. These approaches can be combined in multi-modal treatments. 
Although older studies suggested that these patients should undergone only palliative 
management, in the last 15 year's published studies many authors agree that a multi-modal 
treatment is the modality of choice in selected patients and can achieve a long-term 
remission and a better quality of life. (Anupol, 2002; Brown III, 2005; Chen, 2009; Cohen, 
2004; Cormio, 1995; Cormio, 2003b; Cormio, 2011a; D'Andrea, 2005; Kastritis, 2006; Kim, 
2007; Lee, 2008; Sanderson, 2002; Sehouli, 2010; Tay & Rajesh, 2005). 
An aggressive multimodal approach should be aimed both to cure local and systemic 
disease and leads to an improvement in duration and quality of life.  
Multi centre studies should investigate the better combination of surgery, radiotherapy and 
chemotherapy giving particular attention to the role of different antineoplastic drugs in 
order to find a standard treatment for these patients. 
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